Literature DB >> 2595011

Invasive carcinoma of the uterine cervix following diagnosis and treatment of in situ carcinoma. Record linkage study within a National Cancer Registry.

F Pettersson1, B Malker.   

Abstract

56117 women registered in the Swedish National Cancer Registry with the diagnosis carcinoma in situ of the uterine cervix were followed up and the risk for developing an invasive carcinoma of the uterine cervix was studied. The studied cohort provided 453 362 women years at risk. The primary treatment for carcinoma in situ in Sweden is generally conization. Hysterectomy is carried out in relatively few cases and intracavitary radium treatment was given to a limited number during the period studied. Cryosurgery and laser conization were of less quantitative importance during this period. The incidence rates of invasive carcinoma of the uterine cervix were compared with expected rates calculated from the National Cancer Registry. The ratio between observed and expected number of cases of invasive carcinomas of the uterine cervix is roughly 2.5 from the first year of observation after treatment of the in situ carcinoma until 20 years. There seems to be a distinct difference in risk for development of an invasive carcinoma of the uterine cervix for different age groups. In age group 50 years and older at time for treatment of the in situ lesion, 66 cases of invasive cancer were observed against 10.7 expected - O/E = 6.2. In ages 49 years or less, 145 cases were observed compared with 77.4 expected - O/E = 1.9. The conclusion from this study is that women treated for an in situ lesion are at a higher risk for an invasive carcinoma than the common female population and should be carefully followed up for a long time after treatment of the in situ lesion.

Entities:  

Mesh:

Year:  1989        PMID: 2595011     DOI: 10.1016/0167-8140(89)90028-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study.

Authors:  Björn Strander; Agneta Andersson-Ellström; Ian Milsom; Pär Sparén
Journal:  BMJ       Date:  2007-10-24

2.  Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study.

Authors:  Joy Melnikow; Colleen McGahan; George F Sawaya; Thomas Ehlen; Andrew Coldman
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

3.  Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?

Authors:  Björn Strander; Walter Ryd; Keng-Ling Wallin; Bengt Wärleby; Biying Zheng; Ian Milsom; Baback Gharizadeh; Nader Pourmand; Agneta Andersson-Ellström
Journal:  Eur J Cancer       Date:  2007-07-05       Impact factor: 9.162

4.  Cervical cancer in the screening era: who fell victim in spite of successful screening programs?

Authors:  B Folke Pettersson; Kristina Hellman; Roxane Vaziri; Sonia Andersson; Ann-Cathrin Hellström
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

5.  Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up.

Authors:  Eleftheria Lili; Kimon Chatzistamatiou; Andromachi Kalpaktsidou-Vakiani; Theodoros Moysiadis; Theodoros Agorastos
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

6.  Incidence of cervical cancer after several negative smear results by age 50: prospective observational study.

Authors:  Matejka Rebolj; Marjolein van Ballegooijen; Elsebeth Lynge; Caspar Looman; Marie-Louise Essink-Bot; Rob Boer; Dik Habbema
Journal:  BMJ       Date:  2009-04-24

7.  Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.

Authors:  Matejka Rebolj; Theo Helmerhorst; Dik Habbema; Caspar Looman; Rob Boer; Joost van Rosmalen; Marjolein van Ballegooijen
Journal:  BMJ       Date:  2012-10-31

8.  Uterine cervix cancer treatment at Radiumhemmet: 90 years' experience. Time trends of age, stage, and histopathology distribution.

Authors:  Kristina Hellman; Ann-Cathrin Hellström; B Folke Pettersson
Journal:  Cancer Med       Date:  2014-01-14       Impact factor: 4.452

9.  Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality.

Authors:  Björn Strander; Jonas Hällgren; Pär Sparén
Journal:  BMJ       Date:  2014-01-14

10.  Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.

Authors:  Suzanne M Garland; Jorma Paavonen; Unnop Jaisamrarn; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Xavier Castellsagué; Júlio C Teixeira; S Rachel Skinner; James Hedrick; Genara Limson; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Maria Julieta V Germar; Klaus Peters; M Rowena Del Rosario-Raymundo; Grégory Catteau; Dominique Descamps; Frank Struyf; Matti Lehtinen; Gary Dubin
Journal:  Int J Cancer       Date:  2016-09-09       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.